Quick Takeaways: Why It Matters? The deal adds another science‑forward brand to epiq’s portfolio and deepens its role as a specialty distributor that can take microbiome‑based innovations from H&H/Zesty Paws into the vet channel with supply-chain and market‑access...
Quick Takeaways: Why It Matters? By adding a feline‑specific soft chew built on proprietary CBD + CBDA data, ElleVet deepens its position as a science‑led cannabinoid brand and expands use beyond dogs into a harder‑to‑treat cat population. The palatable, lo...
Quick Takeaways: Why It Matters? By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing. Bundling mast cell detection at no extra c...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
Quick Takeaways: Why It Matters? A-DHA-PT gives veterinary neurologists a standardized, high‑dose DHA option developed under academic supervision, potentially making nutritional add‑on therapy a more routine consideration in dogs with idiopathic epilepsy where pharmacologic con...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
20. ImmuCell Revenue: $18.6M Founded Year: 1982 Market Cap: $35.11M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ 19. Hester Pharmaceuticals & Biotech Revenue: $32M Founded Year: 1987 Market Cap: $150.13 Tota...
